FEATURED NEWS
Dr. Shun Lu said savolitinib plus osimertinib offers a potential new chemo-free treatment option for patients after progression on first-line treatment. Read more
LATEST NEWS
The FDA grants accelerated approval to Dato-DXd while a Biologics License Application for HER3-DXd is voluntarily withdrawn. Read more
Dr. Charles M. Rudin, who presented data from the DeLLphi-304 trial at ASCO 2025, noted that patient-reported outcomes also showed improvements in common symptoms, including dyspne... Read more
Dr. Patrick Forde recently presented milestone data from the trial that confirms the benefit of neoadjuvant-only chemoimmunotherapy for the treatment of resectable lung cancer. Read more